Clozapine efficacy in tardive dyskinesia in schizophrenic patients

  • D.P. Bassitt
  • Mário Rodrigues Louzã Neto
Short communication

DOI: 10.1007/s004060050039

Cite this article as:
Bassitt, D. & Louzã Neto, M. European Archives of Psychiatry and Clinical Neurosciences (1998) 248: 209. doi:10.1007/s004060050039

Abstract

Tardive dyskinesia (TD) is a long-term severe complication of antipsychotic treatment, with mean prevalence of 20–35%. The aim of this study was to evaluate effects of clozapine in severe TD. In an open trial seven patients with schizophrenia and severe TD were given clozapine for 6 months. Tardive dyskinesia severity was evaluated with AIMS and ESRS and schizophrenic psychopathology with PANSS. Clozapine mean dose at the end of the study was 392.86 mg/day. A mean reduction of 52% was observed in ESRS scores for TD. Two patients also had dystonic movements, and there was 50% reduction in one of them and complete remission in the other. There was also a 27% mean reduction in PANSS scores. Clozapine seems to be an alternative in the treatment of schizophrenic patients with severe TD.

Key words Tardive dyskinesia Treatment Clozapine Schizophrenia 
Download to read the full article text

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • D.P. Bassitt
    • 1
  • Mário Rodrigues Louzã Neto
    • 1
  1. 1.Institute of Psychiatry, Medical School, University of São Paulo, Av. Dr. Ovidio Dires de Campos, S/N, São Paulo - SP, CEP 05403-010, Brasil

Personalised recommendations